(R) Cantargia and BioWa extend ongoing collaboration around the POTELLIGENT® Technology
(World News Science)

Lund, Sweden, and Princeton, NJ, USA, August 23, 2019 ---Cantargia AB and BioWa Inc. have signed an extension of the license agreement around the BioWa proprietary POTELLIGENT® Technology for production of Cantargia`s antibody drug candidate CAN04, which gives Cantargia broader rights to use the technology. Since the original agreement allowing use of POTELLIGENT® Technology was signed in 2015, Cantargia has advanced CAN04 to phase IIa clinical development for potential use in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC). Cantargia develops antibody-based pharmaceuticals against the interleukin 1 receptor accessory protein (IL1RAP). The POTELLIGENT®...